FlandersBio on Twitter

Follow us on Twitter

Archive for February 2013 - News

Archive for February 2013 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

ABLYNX SUCCESSFULLY RAISES €31.5 MILLION, IN TOTAL €45 MILLION PLACED

28.02.2013

Ablynx [Euronext Brussels: ABLX], the biopharmaceutical company focused on the discovery and development of Nanobodies®, announces today that it has raised €31.5 million through a private placement of new shares via an accelerated bookbuilding procedure announced on Wednesday 27 February 2013 after the market closed. read more

MDxHealth Reports Fourth Quarter and Fiscal Year 2012 Results

28.02.2013

MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced results for the fourth quarter and the fiscal year ended December 31, 2012. read more

ABLYNX TO RAISE CAPITAL VIA A PRIVATE PLACEMENT OF NEW SHARES

28.02.2013

Ablynx [Euronext Brussels: ABLX], the biopharmaceutical company focused on the discovery and development of Nanobodies®, today announces the launch of a private placement of new sharesto institutional investors for a targeted amount of approximately €20 million. The Company may extend this amount but will in no event place in excess of 10% of the current number of outstanding shares (i.e. a maximum of 4,377,919 new shares). The Board of Directors has decided to cancel the preferential subscription rights of the existing shareholders in the framework of this transaction with respect to the issuance of the new shares, which will take place within the limits of the authorized share capital as set out in the company’s articles of association and in accordance with Article 604 of the Belgian Company Code. read more

Promethera Biosciences opens the French part of its clinical trial in cell therapy

27.02.2013

Promethera Biosciences, a Belgian biotechnology company developing Promethera®HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announces today that it has successfully treated a patient with liver progenitor cells enrolled in its Phase I/II trial. The intervention was performed in January 2013 at the University Children’s Hospital Jeanne de Flandre in Lille (France). read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print